Chinese-based BGM Group Ltd (NASDAQ:BGM) has become one of the more confounding small-cap stories on the Nasdaq, a company reinventing itself repeatedly even as its shares collapsed to well under a dollar. A roughly 6% single-session slide is modest against a backdrop that includes …
Some stocks go quiet because the market is simply waiting; others go quiet because the company behind them has largely stopped operating. Bioasis Technologies Inc. (OTC:BIOAF) falls closer to the second category.
Blue Biofuels Inc sits well outside the health and biotech universe that dominates this coverage: it is a renewable-energy and clean-fuels developer, not a drug or device company, a distinction worth stating up front. Trading over the counter as Blue Biofuels Inc (OTC:BIOF), the …
On a sub-penny stock, a move can amount to a fraction of a cent and a few thousand shares changing hands. That is the context for Bioxytran, Inc. (OTC: BIXT), a tiny over-the-counter biotechnology company whose share price sits around two and a half …
Few Nasdaq-listed companies have reinvented themselves as dramatically as Bonk, Inc (NASDAQ:BNKK). Once a consumer wellness-beverage business, the company has repositioned itself as a public-market vehicle tied to the BONKCryptocurrencyecosystem, an unusual crossover between traditional equities and digital assets.
● Bon Natural Life is the kind of micro-cap that rarely makes headlines, yet its shares nudged higher in early September 2026, drawing a look from investors who track small China-based names on U.S.
Richard A. Roman, a director at NWPX Infrastructure, Inc. (NASDAQ:NWPX), filed a Form 4 on September 10, 2026, disclosing the sale of 4,000 shares of common stock on September 8, 2026, pursuant to a Rule 10b5-1 trading plan.
Aaron Wilkins, Chief Financial Officer of NWPX Infrastructure, Inc. (NASDAQ:NWPX), filed a Form 4 on September 10, 2026, disclosing the sale of 1,500 shares of common stock on September 8, 2026, pursuant to a pre-established Rule 10b5-1(c) trading plan.
A Form 4 filed on September 10, 2026, disclosed that Robert Jones Portman, a director of Procter & Gamble Co (NYSE:PG), acquired 52 shares of common stock on September 8, 2026, in the form of Restricted Stock Units at no cost.
Bone Biologics Corp (NASDAQ: BBLG) sits at the speculative end of the orthobiologics market, a clinical-stage developer worth only a couple of million dollars, whose shares now trade well below a dollar. A soft session and a slow drift lower are what put the …